Drug intelligence / Profile preview

Refluthin

Development stage
Unknown
Lead developer
Schwabe
Modality
Small Molecules
Administration
Oral
01

Overview

Refluthin is a CE-marked medical device developed by Hälsa Pharma GmbH for the rapid and long-lasting relief of heartburn and acid-related gastric discomfort. Formulated as chewable tablets, it contains a combination of calcium carbonate (450 mg), magnesium carbonate (50 mg), and a polysaccharide-rich extract from the prickly pear (*Opuntia ficus-indica*, 75 mg). The product utilizes a dual mechanism of action: the mineral carbonates act as antacids to neutralize excess stomach acid, providing rapid symptom relief, while the prickly pear extract forms a physical mucoprotective film over the esophageal and gastric mucosa to prevent further irritation. Refluthin is marketed as a vegan, aluminum-free option suitable for adults and adolescents aged 12 and older, and its performance and safety have been evaluated in post-market clinical follow-up (PMCF) studies in Germany.

Brand names
RefluthinRefluthin for Heartburn

Beyond the preview

Go deeper on Refluthin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refluthin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call